welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Ursodeoxycholic Acid in the Treatment of Duodenal Adenomas in Familial Adenomatous Polyposis (FAP) Patients
study id #: NCT00134758
condition: Adenomatous Polyposis Coli, Familial
status: status unknown
purpose:Malignant transformation of adenomas of the duodenum is now the leading cause of death in familial adenomatous polyposis (FAP) patients who had a restorative proctocolectomy. Ursodeoxycholic acid (UDCA) modifies the biliary acid profile and could reduce the severity of duodenal adenomas and prevent such transformation.
intervention:
Drug: Ursodeoxycholic acid
Drug: Placebo
expertly curated content related to this topic
-
Thetis Pharmaceuticals Awarded Key Patent on HEALER TechnologyThetis Pharmaceuticals LLC, a privately-...
-
Nutritional Agents With Anti-inflammatory Properties in Chemoprevention of Colorectal NeoplasiaThe strong link between inflammation and...
-
Imatinib for Progressive and Recurrent Aggressive Fibromatosis (Desmoid Tumors): An FNCLCC/French Sarcoma Group Phas...BACKGROUND: Imatinib evaluated as a new...
-
Small Bowel Endoscopic Evaluation in Familial Adenomatous Polyposis (FAP)Background and study aim The relative ri...
-
Familial Adenomatous Polyposis (FAP) Cancer Prevention Pharmaceuticals FAP-310 Clinical Trial Overviewhttps://vimeo.com/144542413...
-
Familial Adenomatous Polyposis by Douglas Riegert Johnsonhttp://www.slideshare.net/douglasriegert...
-
Gliotoxin Inhibits Proliferation and Induces Apoptosis in Colorectal Cancer CellsThe discovery of new bioactive compounds...